Following newborns at risk of eczema to study self-reactive antibodies
Studies when self-reactive antibodies appear in newborns at risk of atopic eczema.
Plain-language title generated from the registry record
Registry title: Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis
Key facts
- Where
- Jette, BelgiumSee the site
Where in Belgium
- Universitair Ziekenhuis (UZ) Brussel, Vrije Universiteit Brussel (VUB)Jette, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitair Ziekenhuis Brussel
- Trial code
- NCT07316465
- Record updated
- 5 January 2026
- Original description
Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as "self-reactive antibodies" or "autoantibodies". It is not yet known when and how these self-reactive antibodies develop, so this is what we aim to investigate.Read full original descriptionShow less
Development of IgE Autoantibodies in Newborns With Atopic Dermatitis (DIANA) Birth Cohort
Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as "self-reactive antibodies" or "autoantibodies". It is not yet known when and how these self-reactive antibodies develop, so this is what we aim to investigate.
This study aims to examine the presence of self-reactive antibodies at birth. In other words, the investigators want to study the earliest stage of developing antibodies that target the body's own skin cells. Additionally, factors that contribute to the development of these self-reactive antibodies will be explored as well as the correlation with the development of atopic eczema.
The study will involve newborns who are at an increased risk of developing atopic eczema due to a family history of asthma, hay fever, or atopic eczema. There will also be a control group of newborns without these characteristics. The study's approach is to examine a portion of the umbilical cord blood, which is routinely collected after birth, to investigate self-reactive antibodies. The goal is to determine whether these self-reactive antibodies are linked to the development of atopic eczema in the first two years of life. For this purpose, follow-ups will be conducted at the ages of 6, 12, and 24 months.
This study will contribute to an increased understanding of the prevalence of self-reactive antibodies and the factors influencing their development. Moreover, the study will determine whether these antibodies play a role in the prevention of and/or serve as predictive factors for the development of atopic eczema.
Inclusion: Newborns who are planned to be born at the maternity ward of UZ Brussel with the following criteria:; 400 newborns with high-risk for AD-development (at least 1 parent or sibling with physician diagnosed atopic dermatitis AND/OR asthma AND/OR allergic rhinitis); 100 newborns with low-risk for AD-development (no parents or siblings with history of atopic dermatitis AND/OR asthma AND/OR allergic rhinitis).
Exclusion: Newborns who are admitted post-partum to the neonatal intensive care unit (gestational age <34 weeks) or with medical complications; Newborns not born at the maternity ward of UZ Brussel; Parents with a poor understanding of Dutch, French or English; Newborns with severe genetic abnormalities/birth defects; Newborns whose parents will not be able to attend the study visits for a period of 2 years (location, working hours).